Agility
SWAT Team Description: Provide cross-cutting support to COVID-19 vaccine developers in the area of diagnostics, standards, assays and animal models.
Co-Leads: Paul Kristiansen (CEPI) and Ivana Knezevic (WHO)
|
 |
Agility
Goal: to enable the rapid assessment of the biological impacts of new variants of SARS-CoV-2.
Aims of the Agility project:
- Rapid identification of new variants of SARS-CoV-2 that may impact COVID-19 vaccines and countermeasures
- Comparative neutralisation testing of identified variants of concern using a panel of sera and WHO International antibody standard
- Assessment of pathogenesis of variants of concern in relevant SARS-CoV-2 animal models
- Timely reports and information sharing on the biological activity (antigenic characteristics and pathogenesis in animals) of emerging variants
- Predictability and comparability achieved through standard procedures and parallel testing in 2 independent laboratories
 |
Early Warning
National initiatives for genomic surveilance
CEPI supports the GISAID Initiative for curation and rapid sharing of global genomic data
|
Alert
Variants of concern identified based on epidemiological, genomic, computational modelling data (notably mutations to spike and receptor binding motif)
|
Response
Variants of concern grown in lab and testing conducted for:
(i) Changes in neutralisation sensitivity (ii) Changes in virulence (iii) Rapid reporting / Information sharing
|
Mitigation
Appropriate actions can be taken by CEPI, public health authorities and developers to adapt pandemic response.
|



Top